TY - JOUR
T1 - Emerging resistance of anaerobic bacteria to antimicrobial agents in South Korea
AU - Lee, Kyungwon
AU - Chong, Yunsop
AU - Jeong, Seok Hoon
AU - Xu, Xue Song
AU - Kwon, Oh Hun
N1 - Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 1996
Y1 - 1996
N2 - In previous studies, Bacteroides fragilis group organisms isolated from Korean patients were more frequently resistant to various antimicrobial agents, including clindamycin, than were isolates in other countries. A recent report of increased resistance of Peptostreptococcus species prompted us to include such isolates in a study of antimicrobial susceptibility. Anaerobes isolated in 1994 at a tertiary care hospital in Seoul were tested by an agar dilution method. None of the B. fragilis group organisms were resistant to imipenem, cefoxitin, chloramphenicol, or metronidazole. However, 6.7% were resistant to ampicillin/sulbactam, 20.2% to cefotetan, 30.3% to piperacillin, 48.3% to cefotaxime, and 42.7% to clindamycin. Almost all of the Clostridium perfringens isolates were susceptible to all of the agents tested, except tetracycline. Peptostreptococcus isolates were susceptible to piperacillin, cefotaxime, and imipenem, while 7.4% were resistant to penicillin G, cefotetan, and metronidazole, and 25.9% were resistant to clindamycin. The isolates resistant to penicillin G, cefotetan, and metronidazole were identified as Peptostreptococcus anaerobius. In conclusion, besides the well-known high rate of resistance of B. fragilis group organisms to clindamycin, the emergence of resistance of Peptostreptococcus species isolates to β-lactam drugs has become obvious in Korea.
AB - In previous studies, Bacteroides fragilis group organisms isolated from Korean patients were more frequently resistant to various antimicrobial agents, including clindamycin, than were isolates in other countries. A recent report of increased resistance of Peptostreptococcus species prompted us to include such isolates in a study of antimicrobial susceptibility. Anaerobes isolated in 1994 at a tertiary care hospital in Seoul were tested by an agar dilution method. None of the B. fragilis group organisms were resistant to imipenem, cefoxitin, chloramphenicol, or metronidazole. However, 6.7% were resistant to ampicillin/sulbactam, 20.2% to cefotetan, 30.3% to piperacillin, 48.3% to cefotaxime, and 42.7% to clindamycin. Almost all of the Clostridium perfringens isolates were susceptible to all of the agents tested, except tetracycline. Peptostreptococcus isolates were susceptible to piperacillin, cefotaxime, and imipenem, while 7.4% were resistant to penicillin G, cefotetan, and metronidazole, and 25.9% were resistant to clindamycin. The isolates resistant to penicillin G, cefotetan, and metronidazole were identified as Peptostreptococcus anaerobius. In conclusion, besides the well-known high rate of resistance of B. fragilis group organisms to clindamycin, the emergence of resistance of Peptostreptococcus species isolates to β-lactam drugs has become obvious in Korea.
UR - http://www.scopus.com/inward/record.url?scp=0029804791&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029804791&partnerID=8YFLogxK
U2 - 10.1093/clinids/23.supplement_1.s73
DO - 10.1093/clinids/23.supplement_1.s73
M3 - Article
C2 - 8953110
AN - SCOPUS:0029804791
VL - 23
SP - S73-S77
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - SUPPL. 1
ER -